Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells

Genes and Development

Volumn 29, Issue 12, 2015, Pages 1298-1315

  Pfister, Neil T ^a   Fomin, Vitalay ^a   Regunath, Kausik ^a   Zhou, Jeffrey Y ^a   Zhou, Wen ^a   Silwal Pandit, Laxmi ^b,c   Freed Pastor, William A ^a,d   Laptenko, Oleg ^a   Neo, Suat Peng ^e   Bargonetti, Jill ^f   Hoque, Mainul ^g   Tian, Bin ^g   Gunaratne, Jayantha ^e,h   Engebraaten, Olav ^c,i   Manley, James L ^a   Børresen Dale, Anne Lise ^b,c   Neilsen, Paul M ^j   Prives, Carol ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^f CITY UNIVERSITY OF NEW YORK   (United States)

^g RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^h NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

ⁱ OSLO UNIVERSITY HOSPITAL   (Norway)

^j SWINBURNE UNIVERSITY OF TECHNOLOGY   (Malaysia)

more..

Author keywords

3D culture; Breast cancer; Chromatin; Mutant p53; SNF; SWI; Transcription; VEGFR2

Indexed keywords

PROTEIN P53; RNA; VASCULOTROPIN RECEPTOR 2; NONHISTONE PROTEIN; NUCLEOSOME; PROTEIN BINDING; SWI-SNF-B CHROMATIN-REMODELING COMPLEX; TRANSCRIPTION FACTOR;

ARTICLE; BINDING AFFINITY; BREAST CANCER CELL; BREAST CANCER CELL LINE; BREAST CELL; CANCER CELL; CELL GROWTH; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; GAIN OF FUNCTION MUTATION; GENE EXPRESSION REGULATION; GENE FUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MUTANT; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN CONFORMATION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RNA SEQUENCE; SWI SNF CHROMATIN REMODELING; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION; UPREGULATION; BREAST TUMOR; GENETICS; HT 29 CELL LINE; MCF 7 CELL LINE; METABOLISM; MUTATION; NUCLEOSOME; PATHOPHYSIOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOMAL PROTEINS, NON-HISTONE; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; MCF-7 CELLS; MUTATION; NUCLEOSOMES; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN CONFORMATION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84933501783     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.263202.115     Document Type: Article

References (70)

1. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, Solari A, Bobisse S, Rondina MB, Guzzardo V, et al. 2009. A Mutant-p53/Smad complex opposes p63 to empower TGFβ-induced metastasis. Cell 137: 87-98.
2. Anders S, Pyl PT, HuberW. 2015. HTSeq-a Python framework to work with high-throughput sequencing data. Bioinformatics 31: 166-169.
3. Bergers G, Benjamin LE. 2003. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410.
4. Bougeard G, Sesboue R, Baert-Desurmont S, Vasseur S, Martin C, Tinat J, Brugieres L, Chompret A, de Paillerets BB, Stoppa-Lyonnet D, et al. 2008. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet 45: 535-538.
5. Braastad CD, Han Z, Hendrickson EA. 2003. Constitutive DNase I hypersensitivity of p53-regulated promoters. J Biol Chem 278: 8261-8268.
6. Brosh R, Rotter V. 2009. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9: 701-713.
7. Bruns AF, Herbert SP, Odell AF, Jopling HM, Hooper NM, Zachary IC, Walker JH, Ponnambalam S. 2010. Ligand-stimulated VEGFR2 signaling is regulated by co-ordinated trafficking and proteolysis. Traffic 11: 161-174.
8. Burrows AE, Smogorzewska A, Elledge SJ. 2010. Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence. Proc Natl Acad Sci 107: 14280-14285.
9. Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ,Wilder S, Lozano G, Pikarsky E, Forshew T, Rosenfeld N, et al. 2013. Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 23: 634-646.
10. Debnath J, Muthuswamy SK, Brugge JS. 2003. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30: 256-268.
11. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A, Blandino G, Piaggio G. 2006. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 10: 191-202.
12. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, et al. 2008. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075.
13. Do PM, Varanasi L, Fan S, Li C, Kubacka I, Newman V, Chauhan K, Daniels SR, Boccetta M, Garrett MR, et al. 2012. Mutant p53 cooperates with ETS2 to promote etoposide resistance. Genes Dev 26: 830-845.
14. Euskirchen GM, Auerbach RK, Davidov E, Gianoulis TA, Zhong G, Rozowsky J, Bhardwaj N, Gerstein MB, Snyder M. 2011. Diverse roles and interactions of the SWI/SNF chromatin remodeling complex revealed using global approaches. PLoS Genet 7: e1002008.
15. Euskirchen G, Auerbach RK, Snyder M. 2012. SWI/SNF chromatin-remodeling factors: multiscale analyses and diverse functions. J Biol Chem 287: 30897-30905.
16. Ferrara N. 2004. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611.
17. Folkman J. 2002. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15-18.
18. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, et al. 1999. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59: 99-106.
19. Freed-Pastor WA, Prives C. 2012. Mutant p53: one name, many proteins. Genes Dev 26: 1268-1286.
20. Freed-PastorWA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, et al. 2012. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148: 244-258.
21. Ghosh S, Sullivan CA, Zerkowski MP, Molinaro AM, Rimm DL, Camp RL, Chung GG. 2008. High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum Pathol 39: 1835-1843.
22. Gomes NP, Bjerke G, Llorente B, Szostek SA, Emerson BM, Espinosa JM. 2006. Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program. Genes Dev 20: 601-612.
23. Guan B, Wang TL, Shih Ie M. 2011. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res 71: 6718-6727.
24. Guo S, Colbert LS, Fuller M, Zhang Y, Gonzalez-Perez RR. 2010. Vascular endothelial growth factor receptor-2 in breast cancer. Biochim Biophys Acta 1806: 108-121.
25. Hanel W, Marchenko N, Xu S, Yu SX, Weng W, Moll U. 2013. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ 20: 898-909.
26. Hoque M, Ji Z, Zheng D, Luo W, Li W, You B, Park JY, Yehia G, Tian B. 2013. Analysis of alternative cleavage and polyadenylation by 3′ region extraction and deep sequencing. Nat Methods 10: 133-139.
27. Jinnin M, Medici D, Park L, Limaye N, Liu Y, Boscolo E, Bischoff J, Vikkula M, Boye E, Olsen BR. 2008. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med 14: 1236-1246.
28. Kadoch C, Hargreaves DC, Hodges C, Elias L, Ho L, Ranish J, Crabtree GR. 2013. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet 45: 592-601.
29. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, Lorenz K, Lee EH, Barcellos-Hoff MH, Petersen OW, et al. 2007. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 1: 84-96.
30. Kim E, Deppert W. 2007. Interactions of mutant p53 with DNA: guilt by association. Oncogene 26: 2185-2190.
31. Krebs JE, Peterson CL. 2000. Understanding 'active' chromatin: a historical perspective of chromatin remodeling. Crit Rev Eukaryot Gene Expr 10: 1-12.
32. Kwon SJ, Park JH, Park EJ, Lee SA, Lee HS, Kang SW, Kwon J. 2015. ATM-mediated phosphorylation of the chromatin remodeling enzyme BRG1 modulatesDNAdouble-strand break repair. Oncogene 34: 303-313.
33. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, et al. 2004. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119: 861-872.
34. Langerod A, Zhao H, Borgan O, Nesland JM, Bukholm IR, Ikdahl T, Karesen R, Borresen-Dale AL, Jeffrey SS. 2007. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 9: R30.
35. Laptenko O, Prives C. 2006. Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ 13: 951-961.
36. Laptenko O, Beckerman R, Freulich E, Prives C. 2011. p53 binding to nucleosomes within the p21 promoter in vivo leads to nucleosome loss and transcriptional activation. Proc Natl Acad Sci 108: 10385-10390.
37. Lee D, Kim JW, Seo T,Hwang SG, Choi EJ, Choe J. 2002. SWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53-mediated transcription. J Biol Chem 277: 22330-22337.
38. Lidor Nili E, Field Y, Lubling Y, Widom J, Oren M, Segal E. 2010. p53 binds preferentially to genomic regions with high DNAencoded nucleosome occupancy. Genome Res 20: 1361-1368.
39. Ludes-Meyers JH, Subler MA, Shivakumar CV, Munoz RM, Jiang P, Bigger JE, Brown DR, Deb SP, Deb S. 1996. Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol Cell Biol 16: 6009-6019.
40. Mo H, Elson CE. 2004. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med (Maywood) 229: 567-585.
41. Mukhopadhyay D, Tsiokas L, Sukhatme VP. 1995. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 55: 6161-6165.
42. Muller PA, Vousden KH. 2014. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 25: 304-317.
43. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, Lukashchuk N, Gillespie DA, Ludwig RL, Gosselin P, et al. 2009. Mutant p53 drives invasion by promoting integrin recycling. Cell 139: 1327-1341.
44. Muller PA, Trinidad AG, Timpson P, Morton JP, Zanivan S, van den Berghe PV, Nixon C, Karim SA, Caswell PT, Noll JE, et al. 2013. Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene 32: 1252-1265.
45. Naidu SR, Love IM, Imbalzano AN, Grossman SR, Androphy EJ. 2009. The SWI/SNF chromatin remodeling subunit BRG1 is a critical regulator of p53 necessary for proliferation of malignant cells. Oncogene 28: 2492-2501.
46. Noll M, Kornberg RD. 1977. Action of micrococcal nuclease on chromatin and the location of histone H1. J Mol Biol 109: 393-404.
47. Noll JE, Jeffery J, Al-Ejeh F, Kumar R, Khanna KK, Callen DF, Neilsen PM. 2012. Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11. Oncogene 31: 2836-2848.
48. Oh J, Sohn DH, Ko M, Chung H, Jeon SH, Seong RH. 2008. BAF60a interacts with p53 to recruit the SWI/SNF complex. J Biol Chem 283: 11924-11934.
49. Olive KP, Tuveson DA, Ruhe ZC, Yin B,Willis NA, Bronson RT, Crowley D, Jacks T. 2004. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119: 847-860.
50. Olivier M, Hollstein M, Hainaut P. 2010. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2: a001008.
51. Patterson C, Wu Y, Lee ME, DeVault JD, Runge MS, Haber E. 1997. Nuclear protein interactions with the human KDR/ flk-1 promoter in vivo. Regulation of Sp1 binding is associated with cell type-specific expression. J Biol Chem 272: 8410-8416.
52. Pishas KI, Al-Ejeh F, Zinonos I, Kumar R, Evdokiou A, BrownMP, Callen DF, Neilsen PM. 2011. Nutlin-3a is a potential therapeutic for ewing sarcoma. Clin Cancer Res 17: 494-504.
53. Quante T, Otto B, Brazdova M, Kejnovska I, Deppert W, Tolstonog GV. 2012. Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity. Cell Cycle 11: 3290-3303.
54. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL, Bedi A. 2000. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev 14: 34-44.
55. Reisman D, Glaros S, Thompson EA. 2009. The SWI/SNF complex and cancer. Oncogene 28: 1653-1668.
56. Risso D, Ngai J, Speed TP, Dudoit S. 2014. Normalization of RNA-seq data using factor analysis of control genes or samples. Nat Biotechnol 32: 896-902.
57. Ryden L, Linderholm B, Nielsen NH, Emdin S, Jonsson PE, Landberg G. 2003. Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res Treat 82: 147-154.
58. Ryme J, Asp P, Bohm S, Cavellan E, Farrants AK. 2009. Variations in the composition of mammalian SWI/SNF chromatin remodelling complexes. J Cell Biochem 108: 565-576.
59. Schneider CA, Rasband WS, Eliceiri KW. 2012. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9: 671-675.
60. Song H, Hollstein M, Xu Y. 2007. p53 gain-of-function cancer mutants induce genetic instability by inactivatingATM. Nat Cell Biol 9: 573-580.
61. Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z, Shiff I, Kogan I, Shay M, Kalo E, et al. 2010. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 17: 273-285.
62. Strobeck MW, Knudsen KE, Fribourg AF, DeCristofaro MF, Weissman BE, Imbalzano AN, Knudsen ES. 2000. BRG-1 is required for RB-mediated cell cycle arrest. Proc Natl Acad Sci 97: 7748-7753.
63. TolstorukovMY, Sansam CG, Lu P, Koellhoffer EC, Helming KC, Alver BH, Tillman EJ, Evans JA, Wilson BG, Park PJ, et al. 2013. Swi/Snf chromatin remodeling/tumor suppressor complex establishes nucleosome occupancy at target promoters. Proc Natl Acad Sci 110: 10165-10170.
64. Vousden KH, Prives C. 2009. Blinded by the light: the growing complexity of p53. Cell 137: 413-431.
65. Walerych D, Napoli M, Collavin L, Del Sal G. 2012. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 33: 2007-2017.
66. Weissmueller S, Manchado E, Saborowski M, Morris JP, Wagenblast E, Davis CA, Moon SH, Pfister NT, Tschaharganeh DF, Kitzing T, et al. 2014. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling. Cell 157: 382-394.
67. Werner H, Karnieli E, Rauscher FJ, LeRoith D. 1996. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci 93: 8318-8323.
68. Wilson BG, Roberts CW. 2011. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 11: 481-492.
69. Xia W, Nagase S, Montia AG, Kalachikov SM, Keniry M, Su T, Memeo L, Hibshoosh H, Parsons R. 2008. BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. Cancer Res 68: 1667-1674.
70. Xu Y, Zhang J, Chen X. 2007. The activity of p53 is differentially regulated by Brm-and Brg1-containing SWI/SNF chromatin remodeling complexes. J Biol Chem 282: 37429-37435.